TORONTO and HOUSTON, TX, Oct. 18,
2017 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna"
or the "Company") (TSX: MDNA; OTCQX: MDNAF), a clinical stage
immuno-oncology company, is pleased to announce that the Company
has received approval to commence trading on the OTCQX Best Market,
under the symbol, "MDNAF". The Company's shares continue to
trade on the Toronto Stock Exchange ("TSX") under the symbol
"MDNA".
OTCQX is an established market for global and growth companies
with high financial standards. Investors can find current financial
disclosure and Real-Time Level 2 quotes for Medicenna at
www.otcmarkets.com.
"We are very pleased to be trading on the OTCQX as it will
improve the Company's ability to attract a wider audience of
investors from both inside and outside the United States. This corporate milestone
will provide additional visibility within the investment community
enabling us to build awareness more broadly and expand our current
shareholder base in order to drive shareholder value", said
Elizabeth Williams, Chief Financial
Officer of Medicenna.
"Medicenna Therapeutics joins an impressive roster of Canadian
companies, including more than 25 added this year, that cross-trade
their shares on the OTCQX market to maximize their reach to U.S.
investors. Trading on OTCQX will enable Medicenna to efficiently
broaden accessibility to their news and financial disclosure and
build visibility among U.S. investors," said Jason Paltrowitz, Executive Vice President of
Corporate Services at OTC Markets Group.
Medicenna Therapeutics was sponsored for OTCQX by Burns Figa
& Will PC, a qualified third-party firm responsible for
providing guidance on OTCQX requirements and recommending
membership.
About Medicenna Therapeutics Corp.
Medicenna is a
clinical stage immuno-oncology company developing novel highly
selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in
class Empowered Cytokines™ (ECs). Its wholly owned subsidiary,
Houston-based Medicenna BioPharma, is specifically targeting the
Interleukin-4 Receptor (IL4R), which is over-expressed by at least
20 different types of cancer affecting more than one million new
cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is
enrolling patients in a CPRIT (Cancer Prevention and Research
Institute of Texas) funded Phase
2b clinical trial for recurrent glioblastoma (rGBM) at leading
brain cancer centres in the US. MDNA55 has completed 3 clinical
trials in 72 patients, including 66 adults with rGBM, demonstrated
compelling efficacy and obtained Fast-Track and Orphan Drug status
from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs
have the potential to purge both the tumor and the
immunosuppressive tumor microenvironment, offering a unique
treatment paradigm for a large majority of cancer patients.
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture
Market, and the Pink® Open Market for 10,000 U.S. and global
securities. Through OTC Link® ATS, OTC Markets connects a
diverse network of broker-dealers that provide liquidity and
execution services. The company enables investors to easily
trade through the broker of their choice and empower companies to
improve the quality of information available for investors.
To learn more about how OTC Markets creates better informed and
more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC
regulated ATS.
For more information, please visit www.medicenna.com.
This news release contains forward-looking statements
relating to the future operations of the Company and other
statements that are not historical facts. Forward-looking
statements are often identified by terms such as "will", "may",
"should", "anticipate", "expects" and similar expressions. All
statements other than statements of historical fact, included in
this release, including, without limitation, statements regarding
the ability of the company to add new shareholders, increase
shareholder value, future plans and objectives of the Company and
others are forward-looking statements that involve risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and actual results and future events could
differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ
materially from the Company's expectations include the risks
detailed in the annual information form of the Company dated
June 15, 2017 and in other filings
made by the Company with the applicable securities regulators from
time to time.
The reader is cautioned that assumptions used in the
preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to
differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of
which are beyond the control of the Company. The reader is
cautioned not to place undue reliance on any forward-looking
information. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made
as of the date of this news release and the Company will update or
revise publicly any of the included forward-looking statements only
as expressly required by Canadian securities law.
SOURCE Medicenna Therapeutics Corp.